LTRN

+ Watchlist + Portfolio

Lantern Pharma Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.49
52-Week Range: $1.11 – $4.70
Market Cap: $29.28M
P/E (TTM): —
EPS (TTM): -1.63
Dividend Yield: —

Advanced Metrics

Price/Book: 7.48
PEG Ratio: —
Return on Equity: -157.37%
Return on Assets: -73.31%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 1.87
Debt/Equity: 0.02
Total Debt: $59.08K
Free Cash Flow: $-8.99M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $23.69M

LTRN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$8.60M	$11.89M	$16.13M	$11.51M
Selling, General & Admin	$5.83M	$5.98M	$6.09M	$6.46M
Operating Expenses	$14.43M	$17.88M	$22.22M	$17.98M
Operating Income	-$14.43M	-$17.88M	-$22.22M	-$17.98M
EBITDA	-$14.42M	-$17.86M	-$22.20M	-$17.96M
Pretax Income	-$14.26M	-$15.96M	-$20.78M	-$17.12M
Net Income	-$14.26M	-$15.96M	-$20.78M	-$17.12M
Diluted EPS	-1.31	-1.47	-1.93	-1.57
Diluted Shares	10.85M	10.84M	10.76M	10.90M

LTRN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$37.20M	$21.94M	$7.51M	$4.42M
Current Assets	$58.72M	$43.34M	$25.25M	$10.80M
Total Assets	$58.84M	$43.65M	$25.57M	$11.04M
Current Liabilities	$2.80M	$2.68M	$4.33M	$4.50M
Total Debt	$52.89K	$234.47K	$243.66K	$78.54K
Total Liabilities	$2.80M	$2.74M	$4.38M	$4.50M
Retained Earnings	-$39.28M	-$55.24M	-$76.03M	-$93.15M
Shareholders' Equity	$56.04M	$40.91M	$21.19M	$6.53M
Working Capital	$55.92M	$40.66M	$20.92M	$6.30M

LTRN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$12.77M	-$14.35M	-$17.81M	-$15.68M
Capital Expenditure	-$27.84K	-$18.73K	-$12.60K	-$1.72K
Free Cash Flow	-$12.80M	-$14.37M	-$17.83M	-$15.68M
Depreciation & Amortisation	$10.08K	$14.62K	$17.28K	$17.28K
Stock-Based Compensation	$1.19M	$1.07M	$732.89K	$650.88K
Investing Cash Flow	$179.27K	-$930.21K	$3.37M	$11.06M
Financing Cash Flow	-$2.18M	-$500.00K	$66.71K	$1.50M
Share Repurchases	-$2.48M	-$500.00K	—	—
Net Change in Cash	-$14.77M	-$15.78M	-$14.38M	-$3.12M

LTRN Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$3.26M	$3.07M	$2.44M	$2.74M	$1.72M
Selling, General & Admin	$1.51M	$1.58M	$1.91M	$1.46M	$1.68M
Operating Expenses	$4.77M	$4.65M	$4.35M	$4.20M	$3.41M
Operating Income	-$4.77M	-$4.65M	-$4.35M	-$4.20M	-$3.41M
EBITDA	-$4.77M	-$4.65M	-$4.35M	-$4.20M	-$3.40M
Pretax Income	-$4.54M	-$4.33M	-$4.18M	-$4.07M	-$3.33M
Net Income	-$4.54M	-$4.33M	-$4.18M	-$4.07M	-$3.33M
Diluted EPS	-0.42	-0.40	-0.39	—	-0.30
Diluted Shares	10.78M	10.78M	10.83M	—	11.25M

LTRN Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$6.38M	$6.06M	$8.39M	$4.42M	$4.92M
Current Assets	$20.82M	$17.20M	$13.46M	$10.80M	$7.06M
Total Assets	$21.10M	$17.42M	$13.63M	$11.04M	$7.22M
Current Liabilities	$4.29M	$4.88M	$4.04M	$4.50M	$3.78M
Total Debt	$194.93K	$145.04K	$93.95K	$78.54K	$59.08K
Total Liabilities	$4.32M	$4.90M	$4.04M	$4.50M	$3.78M
Retained Earnings	-$80.56M	-$84.89M	-$89.07M	-$93.15M	-$96.47M
Shareholders' Equity	$16.78M	$12.52M	$9.59M	$6.53M	$3.45M
Working Capital	$16.54M	$12.32M	$9.42M	$6.30M	$3.28M

LTRN Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$4.38M	-$3.94M	-$4.57M	-$2.79M	-$3.77M
Capital Expenditure	-$1.16K	—	-$555.00	-$1.00	—
Free Cash Flow	-$4.38M	-$3.94M	-$4.57M	-$2.79M	-$3.77M
Depreciation & Amortisation	$4.57K	$4.50K	$4.10K	$4.10K	$3.85K
Stock-Based Compensation	$147.75K	$160.63K	$143.69K	$198.82K	$262.92K
Investing Cash Flow	$3.24M	$3.59M	$5.93M	-$1.70M	$4.25M
Financing Cash Flow	$0.00	$0.00	$971.78K	$526.46K	—
Net Change in Cash	-$1.14M	-$344.12K	$2.33M	-$3.97M	$477.37K

Market Snapshot

About

Lantern Pharma Inc. is an artificial intelligence-driven oncology biotechnology company using machine learning and genomics to develop targeted cancer therapies. The company leverages its proprietary RADR AI platform to identify drug candidates and patient biomarkers for precision oncology treatments. Lantern is advancing multiple clinical programs targeting various cancer types with a focus on rescued drugs and novel combinations.